Candela Delivers the Next Advancement for Improving Patient Comfort without Compromising Results.

WAYLAND, Mass. -- Candela Corporation (NASDAQ:CLZR) today announced the release of the next generation Serenity[TM] Pro system to be featured at the 66th Annual Meeting of the American Academy of Dermatology in San Antonio from February 1-5, 2008. The newly enhanced system provides users with improved ease of use through automatic contact sensing technology with single touch laser activation making treatments easier and quicker. In addition, a new integrated handpiece has been designed to exclusively work with the Candela GentleLASE[R] and GentleYAG[R] systems.

The Serenity Pro system relies on Pneumatic Skin Flattening (PSF; a proprietary and patented technology) to inhibit pain during laser or light-based aesthetic treatments. Candela received the FDA clearance for the Serenity device using the PSF technology for pain reduction in October 2007 and generated product interest in the aesthetic community as a must have product for practice differentiation. On January 10, 2008 the Serenity Pro received the additional FDA clearance for reduction of pain during laser and Intense Pulsed Light (IPL) treatments. According to Millennium Research, the installed base of lasers and IPLs is estimated to be 70,000 worldwide.

Many well known global opinion leaders have adopted the PSF technology into their practices and have seen the difference. With the new improvements to the system, Candela is positioned to make the Serenity Pro a standard of care for patients seeking comfort during treatments without compromising results.

"The benefits of Serenity Pro enable Candela to further strengthen our competitive position in the aesthetic laser market," said Catherine A. Kniker, Senior Vice President, Corporate Strategic Development. "Likewise, customers are looking for an edge over the competition. With Serenity Pro, our sales organization can deliver a solution to customers that will help differentiate and grow their practices."

See the Serenity Pro for yourself by visiting the Candela booth #2501 at AAD, or for more information visit www.candelagetthere.com.

About CANDELA: Candela Corporation manufactures, and distributes innovative clinical solutions that enable physicians, surgeons, and personal care practitioners to treat selected cosmetic and medical conditions using lasers, aesthetic laser systems, and other advanced technologies. Founded near Boston in 1970, the company markets and services its products in over 70 countries from offices and distributors in the United States, Europe, Japan, China and other Asian locations. Candela established the aesthetic laser market 18 years ago, and currently has an installed base of an estimated 12,000 lasers worldwide. Visit Candela on the Web at http://www.candelalaser.com.

Safe Harbor Statement: Except for the historical information contained herein, this news release contains forward-looking statements that constitute Candela's current intentions, hopes, beliefs, expectations or predictions of the future, which are therefore inherently subject to risks and uncertainties. Such statements may relate to, among other things, our future revenue, gross margin, expense levels and earnings, our growth prospects, market acceptance of our products, the strength of our distribution channels, our ability to add new products, our ability to expand regulatory approvals and the liquidity of our common stock. The risks and uncertainties that may affect forward-looking statements include, among others: the cancellation or deferral of customer orders, the risk of an adverse judgment in the patent litigation with Palomar Medical Technologies, Inc., dependence on a small number of strategic distribution relationships, difficulties in the timely development and market acceptance of new products, unanticipated increases in expenses, market developments that vary from the current public expectations concerning the growth of the laser industry, increased competitive pressures, changes in economic conditions, or difficulties in obtaining timely regulatory approvals. Further information on factors that could affect Candela's performance is included in Candela's periodic reports filed with the SEC. Candela cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Candela expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Candela's expectations or any change in events, conditions or circumstances on which any such statement is based.